Notice of Intent to Award Sole Source & Redacted J&A Reagents: GBS, IVD, S. Aureus and MRSA, C. Difficile/Epi, Flu, Strep A, and Flu/RSV compatible with Cepheid GeneXpert XVI analyzer

This Special Notice from the Department of the Army Medical Command provides advance notification of its intent to award a sole source contract. The Fort Hood Health Contracting Cell Regional Health Contracting Office, Central Army Health Contracting Activity, MEDCOM, Fort Hood, Texas intends to award a firm fixed-price, sole source contract to Roche Diagnostics Corporation for reagents compatible with the Cepheid GeneXpert XVI analyzer for Carl R. Darnall Army Medical Center, Fort Hood, Texas.

The reagents include GBS, IVD, S. Aureus and MRSA, C.Difficile/Epi, Flu, Strep A, and Flu/RSV. The notice specifies the contracting officer determined only one responsible source was available for these reagents. No requests for capability briefings or information provided in response to the notice will be considered for a subsequent solicitation. The contract award is intended to be made on or about September 24, 2021 to Cepheid for these reagents to enable the Carl R. Darnall Army Medical Center to test for various pathogens using the Cepheid GeneXpert XVI molecular analyzer. A justification document demonstrates that only Cepheid can provide all necessary FDA-approved tests to run on this analyzer as its sole manufacturer.